This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

ONLINE REGISTRATION CLOSES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Dr. Aude Segaliny, PhD
Senior Director, Head of Research & Early Development at Amberstone Biosciences
Speaker

Profile

Dr. Aude Segaliny has over 15 years of experience in immunology, cell biology, cytokine and receptor biology, microfluidic single-cell functional screening platform, and in vitro/in vivo characterization assays, with a focus on cancer therapeutics discovery. She is an accomplished scientist and R&D leader in cancer research and preclinical pharmacology. As a founding scientist of Amberstone Biosciences, Dr. Segaliny has played a pivotal role in advancing the company’s Tumor-Microenvironment Activated Therapeutics (T-MATE™) platform, successfully driving critical projects and achieving key milestones, including bringing lead candidates to the pre-IND stage. Known for her strong leadership, Dr. Segaliny fosters effective communication and collaboration between internal teams, external collaborators, advisors, and partners.

Agenda Sessions

  • A New Generation of Tumor-Microenvironment Activated ThErapeutic (T-MATE) to Treat Solid Tumors

    5:45pm